IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors in home settings

IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors in home settings

IMPORTANT INFORMATION on minimising the risk of hypersensitivity reactions and medication errors during home infusion

Enbrel Patient Card

patient reminder card

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Carry Card for EpiPen® patients

Trainer Pen order form

Travel Certificate for those carrying EpiPen®

Guide to Using Your EpiPen® & Trainer EpiPen® leaflet

Checklist for EpiPen and EpiPen Jr

Educational materials for patients on importation safety information card for valproate - Contraception and Pregnancy Prevention

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Healthcare Professional (HCP) educational material on important safety information associated with Valproate use.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

FOR DISPENSARY USE ONLY Pharmacy poster with key information about the Pregnancy Prevention Programme.

Female Patient Guide on important safety information associated with Valproate use - educational material

Male Patient Guide on important safety information associated with Valproate use - educational material

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

The aim of this brochure is to educate and/or remind healthcare professionals about the selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns associated with eculizumab.

This guide is intended to explain important safety information of eculizumab to patients and parents/caregivers of infants and children who are prescribed eculizumab.

Important Safety Information for Patients Receiving EPYSQLI. Show this card to any doctor involved in your care.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

The DHPC letter contains detailed safety information on the ready-to-use solution for infusion (1 mg/mL) and highlights some key differences in the packaging from the existing single/multidose concentrate formulation (100 mg/mL).

Hospital admission kit consisting of a letter and chart sticker providing actionable communication to HCPs.

To minimize patient harm associated with the use of non-glucose-specific monitors and test strips by providing HCPs and patients with electronic access to a reference list showing the compatibility of Extraneal with key glucometer manufacturers.

Hospital admission kit consisting of a letter and chart sticker providing actionable communication to HCPs

Wallet card which concisely communicates the risk of potential incorrect blood glucose reading to HCPs (potentially on behalf of an unconscious patient)

Patient guide to explain the use of Eydenzelt with multiple conditions

Prescriber guide to the use of Eydenzelt

QR code leaflet to provide QR codes to patient guide

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

Your guide to Eylea - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)

Eylea Prescriber Guide (v9.0) for Eylea 40 mg/ml and Eylea 114.3 mg/ml

Information for parents and caregivers – for the treatment of retinopathy of prematurity (ROP)

Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).